A Powerhouse of the Global Chemical Pharmaceutical Industry
Celltrion Pharm develops, manufactures, and sells chemical pharmaceuticals for various disease areas, including circulatory, endocrine, digestive medicine, and antibodies. We continue to invest in facilities and carry out R&D projects to develop new growth engines and create new values. Moreover, we continue to expand our product portfolio to increase our market share.
Godex Capsule is one of Celltrion Pharm’s main products and the market leader in liver disease medicine (ranked first in outpatient prescription among hepatotonics as of 2020 based on UBIST). It has been proven to effectively lower liver enzymes and treat non-alcoholic fatty liver disease(NAFLD)fatty liver symptoms. As such, the company is working toward increasing its market share. Other than Godex, Celltrion Pharm has also successfully launched various chemical pharmaceuticals in the market, including hypertension and hyperlipidemia fixed dose combination medicines with improved treatment compliance.
Celltrion Group is expanding and bolstering strategic partnerships with other pharmaceutical companies inside and outside of Korea. By expanding its product portfolio, the company provides a wider range of treatment options for physicians and patients. As a part of the Celltrion Group, Celltrion Pharm will build partnerships with leading pharmaceutical companies worldwide to consolidate its position in the global market and improve its competitive edge.
The Celltrion Group carries out Global Chemical Projects to expand its portfolio and boost its sales. The group performs related tasks through two affiliates: Celltrion Chemical Business Headquarters, which oversees the overall projects, and Celltrion Pharm, in charge of the research and production functions. The two organizations consult with each other for technical analysis, identifying candidate products,
and co-developing product portfolios. Through these efforts, the group supplies HIV medicines, as well as endocrine and digestive medicines, to global markets.